Clinical Trial Update: A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. [Phase 3]

View source ↗

Summary

Phase 3 study to assess change in disease activity and adverse events with cariprazine for depressive episodes in pediatric participants (10 to 17 years) with B…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• VRAYLAR (cariprazine)

Snippet

Sponsor: AbbVie | Conditions: Depression, Bipolar I Disorder | Phase 3 | Status: RECRUITING